Conjustar Biologics (星联肽生物), a clinical-stage biotech company focused on miniaturized conjugate drugs—peptide-drug conjugates (PDCs) and Nanobody-drug conjugates (NDCs)—has been awarded to PharmCube's "Top 15 Emerging Innovative Drug Enterprises in China (2025)" at the 2026 OneBD Pharmaceutical Investment & BD Conference, held May 21 in Shanghai.
Conjustar announced the completion of ￥100 million Pre-A+ round of financing. This round of financing was led by Fosun health Capital New Drug Innovation Fund of Fosun Pharmaceutical, and co-invested by Hengqin Venture Capital and Shenzhen Qianhai Liyuan.
